drugset
drugset / Trial / NCT05249569

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

NCT05249569 ↗

Phase 2 Terminated 1 enrolled University of Texas Southwestern Medical Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden. Treatment beyond progression should be considered when the patient is stable (or improving) symptomatically and if tumor reassessment can be performed within a short period.

Timeline

Start
2022-11-04
Primary completion
2022-12-30
Completion
2022-12-30

Outcome

Outcome not reported

Stopped: “Sponsor pulled support for one of the study drugs.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Avelumab Monoclonal antibody 10 mg/kg Intravenous
Subject Axitinib Small molecule 5 mg Oral
Subject Bavituximab Monoclonal antibody 3 mg/kg Intravenous

Indications

hepatocellular carcinoma